Drug intelligence / Profile preview

DWC202310 + DWC202311

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules

Overview

DWC202310 + DWC202311 is a combination of two investigational small molecule drugs developed by Daewoong Pharmaceutical. This combination has been studied in clinical trials to compare its pharmacokinetics and safety profile with DWJ-1558, another compound from the same developer. The specific mechanisms of action, targets, and therapeutic indications for DWC202310 and DWC202311 have not been disclosed in public sources as of June 2025. The available data indicate that the combination is being evaluated in healthy volunteers for bioequivalence and safety[4].

Beyond the preview

Go deeper on DWC202310 + DWC202311.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202310 + DWC202311.

Explore the full profile